SON-1010
Phase 1Active 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Trial Timeline
Apr 20, 2022 → Jun 30, 2026
NCT ID
NCT05352750About SON-1010
SON-1010 is a phase 1 stage product being developed by Sonnet BioTherapeutics for Advanced Solid Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT05352750. Target conditions include Advanced Solid Tumor, Soft Tissue Sarcoma Adult.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05756907 | Phase 1/2 | Terminated |
| NCT05352750 | Phase 1 | Active |
Competing Products
20 competing products in Advanced Solid Tumor